On paper, September 30 should have been a green day. Domestic institutional investors bought ₹11,271.70 crore of Indian equities in the cash segment, outpacing the ₹10,148.40 crore foreign institutional investors sold — a net institutional inflow of roughly ₹1,123 crore. Two sessions ago, on September 29, DIIs hadn't managed to close that gap at all. Today they cleared it outright. The Nifty fell anyway, down 95.75 points (0.42%) to close at 22,620.45, extending Monday and Tuesday's losses into a third straight session. The Sensex slipped a smaller 0.07% to 72,480, down from Tuesday's 72,529.07.
Net buying isn't the same as broad buying, and today is the gap between those two things. Six of the ten NSE sector indices actually closed higher — but only 17 of the Nifty's 50 constituent stocks rose. The domestic money that outbought foreign sellers went almost entirely into one place: banks.
Where the money actually went
Bank Nifty closed up 0.69% even as the benchmark fell, led by ICICI Bank (+2.38%), Kotak Mahindra Bank (+2.25%) and IndusInd Bank (+1.86%). Nifty Realty was the day's best-performing sector gauge, up 1.62%. Against that, Nifty Pharma was the worst sector performer, down 1.84%, and three large-cap names did most of the damage at the index level: Eternal (down 2.71%), Adani Ports (down 2.41%) and Nestle India (down 2.32%).
| Mover | Change |
|---|---|
| ICICI Bank | +2.38% |
| Kotak Mahindra Bank | +2.25% |
| IndusInd Bank | +1.86% |
| Nifty Realty (sector) | +1.62% |
| Nestle India | −2.32% |
| Adani Ports | −2.41% |
| Eternal | −2.71% |
| Nifty Pharma (sector) | −1.84% |
India VIX held at 13.50 — low enough that none of this reads as panic selling. It reads as rotation: money moving into financials and realty while pharma, FMCG and port-linked names were sold down, and the index-weight math on the losing side simply outweighed the winning side.
Why banks, specifically, right now
The rotation into financials isn't happening in a vacuum. Results season for the quarter just ended opens in the first half of October, and the bank going first into it, ICICI Bank, enters from a position of genuine strength: advances grew nearly 20% year-on-year in the June quarter, net interest income rose 12.7% to ₹24,384 crore, net interest margin held around 4.36%, return on assets sat at roughly 2.49%, and credit costs stayed low with asset quality improving rather than deteriorating. That isn't an isolated case. Sector-wide, brokerage estimates point to net interest income growing around 11% and loan books growing about 18% for the June quarter, with strong FCNR deposit inflows and healthy credit demand cited as the drivers carrying into the current quarter. When a sector is showing double-digit loan and income growth heading into earnings, it's a plausible place for domestic money to concentrate even while the rest of the tape is under pressure — a fundamentals-driven rotation ahead of results, layered on top of whatever else is moving the index today.
Pharma sits on the opposite side of that logic. The sector has traded under an overhang for much of 2026 from the prospect of higher US tariffs on branded and generic drug imports — the US being the largest overseas market for Indian drugmakers by revenue — and today's 1.84% sector decline fits a pattern of pharma being sold whenever that risk resurfaces, rather than a one-off move tied to a single headline.
A rate decision in the background
Sitting underneath all of this is a Reserve Bank of India policy review just days away: the Monetary Policy Committee meets October 5-7, and a poll of economists and treasury heads has the RBI raising the repo rate by 25 basis points to 5.50%, up from the 5.25% it held at its August review. The case for a hike has been building: retail inflation accelerated to a provisional 4.82% year-on-year in August, Brent crude has pushed back above $100 a barrel on renewed geopolitical tensions, and the rupee has been one of the weaker Asian currencies this year, down roughly 6.5% against the dollar year-to-date and trading in a 95.50-96.10 band. None of that is what moved today's index on its own, but it's the backdrop every sector call this week is being made against — and a banking sector heading into earnings with strong loan growth is a different bet under a rising-rate scenario than a rate-sensitive sector like realty, which rallied today despite that same backdrop typically working against it.
The bigger number underneath
FIIs have now been net sellers through almost all of September, a run that resumed after a two-month buying streak in July and August. Today's ₹10,148.40 crore outflow adds to the roughly ₹17,131 crore FIIs had already pulled out through the rest of the month — putting the month's cumulative foreign selling in the neighbourhood of ₹27,000 crore, among the heaviest single-month outflows the market has logged this year. DIIs have absorbed nearly all of it on most days, today included, and that absorption is the only reason the index isn't down considerably more than a third of a percent.
What today adds to that picture is the concentration. A market where domestic buying outpaces foreign selling but still closes lower is a market where the buying isn't spread widely enough to lift the average stock — it's propping up a handful of large, liquid names, banks chief among them, while everything outside that pocket keeps drifting down. Whether that narrow participation can keep holding the index up if foreign selling continues at September's pace is the question the next few sessions will answer, not this one.